National Cancer Center to promote multidisciplinary diagnosis and treatment of cancer

On October 26, Cai Jianqiang, deputy director of the National Cancer Center and vice president of the Cancer Hospital of the Chinese Academy of Medical Sciences, said at the third Huaxia Cancer Summit Forum recently that under the multi-disciplinary diagnosis and treatment mode, the development of accurate and personalized treatment plan can prolong the life of patients with advanced cancer, and even give them a chance to cure. The National Cancer Center will promote the MDT model in an all-round way to help achieve the goals of China’s cancer prevention and control action. < p > < p > MDT refers to the mode of taking the patient as the center, combining with the multidisciplinary experts to discuss and discuss, so as to clarify the diagnosis stage and formulate the appropriate treatment plan for the patients. From 2018 to 2020, the National Health Commission has carried out tumor MDT pilot work nationwide. Cai Jianqiang said that at present, the common diagnosis and treatment mode for cancer patients in China is that whoever is the first to “catch” the patient will see, and often “cure the head with headache and cure the foot with pain”. In such a treatment mode, patients may receive repeated examination, over treatment, improper treatment, etc., resulting in missing the best treatment opportunity. What is the significance of MDT in patients with advanced cancer? Taking the high incidence of colorectal cancer in China as an example, due to the occult onset and no obvious symptoms in the early stage, it is easy to miss diagnosis, metastasis and recurrence, and many patients have found that it is already advanced. Cancer Hospital of Chinese Academy of Medical Sciences took the lead in establishing MDT collaboration group for colorectal cancer liver metastasis in 2007, and successively established expert consensus and special disease association. The data show that the 5-year survival rate of patients receiving MDT collaboration group is 46%, which has reached the international advanced level. The overall 5-year survival rate of cancer will not be less than 46.6% by 2030. A number of participating academicians and experts in the field of cancer said that China’s current incidence rate and mortality rate is much higher than that of the digestive system tumors, such as esophageal cancer, gastric cancer, and intestinal cancer. The application of MDT can significantly improve the 5-year survival rate of this kind of tumor, which is of great significance to achieve the goal of cancer prevention and treatment.